Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23789741 | 1.00 | KMT2A (0.49) | KMT2AMEN1EPHX2ALDH1A1LMNA | |
| SCHEMBL25446863 | 0.89 | EPHX2 (0.44) | KMT2AMEN1EPHX2ALDH1A1LMNA | |
| SCHEMBL23945950 | 0.87 | KMT2A (0.44) | KMT2AMEN1EPHX2ALDH1A1LMNA | |
| SCHEMBL23945482 | 0.87 | KMT2A (0.44) | KMT2AMEN1EPHX2ALDH1A1LMNA | |
| SCHEMBL5066367 | 0.87 | MEN1 (0.50) | KMT2AMEN1EPHX2ALDH1A1LMNA | |
| SCHEMBL22821424 | 0.85 | MEN1 (0.47) | KMT2AMEN1EPHX2ALDH1A1LMNA | |
| SCHEMBL25971293 | 0.83 | MEN1 (0.49) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL25138073 | 0.83 | MEN1 (0.49) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL21946773 | 0.83 | MEN1 (0.49) | KMT2AMEN1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16978269 | 0.82 | ALDH1A1 (0.57) | KMT2AALDH1A1LMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241227-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | KMT2A 1286/4885MEN1 4516/4885EPHX2 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.